Toshali Pandey

Resident physician

UAMS University of Arkansas primary

Also affiliated: University of Arkansas Medical Center (2025); Maulana Azad Medical College (2022–2023)

Faculty Researcher

2 h-index 21 pubs 11 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website

OverviewAI-generated summary

Toshali Pandey's research focuses on various aspects of medical science, with recent publications exploring the impact of the COVID-19 pandemic on gastroenterology training and quality of life assessments for patients with esophageal strictures. Pandey has also investigated the utility of immunocytochemistry on destained smears as an alternative to conventional techniques. Further work examines immune cell profiling in response to CAR-T cell therapy for multiple myeloma, the predictive value of drug-induced rashes for survival in mycosis fungoides/sezary syndrome, and risk factors for acute kidney injury in patients receiving CAR-T cells. Collaborations include shared publications with Bhavesh Mohan Lal, Ankur Varma, Sajjad Akbar Bhatti, and J. Curran Henson at the University of Arkansas for Medical Sciences.

Metrics

h-index: 2
Publications: 21
Citations: 11

Selected Publications

Multi-antigen chimeric antigen receptor-T cell therapy for relapsed/refractory B cell lymphomas (2026)

Frontiers in Immunology DOI OpenAlex
Acute Kidney Injury in Recipients of Chimeric Antigen Receptor T-Cell Therapy: Clinical Characteristics and Impact on Mortality (2026)

Transplantation and Cellular Therapy DOI OpenAlex
Demographic and regional trends in combined colorectal cancer and cerebrovascular disease-related mortality in the United States (1999–2023). (2026)

Journal of Clinical Oncology DOI OpenAlex
Cardiovascular outcomes of durvalumab versus pembrolizumab in gastric cancer: A propensity-matched TriNetX analysis. (2026)

Journal of Clinical Oncology DOI OpenAlex
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)

Blood Cancer Journal 1 citation DOI OpenAlex
Can the development of drug-induced rash after mogamulizumab administration predict survival in mycosis fungoides/sezary syndrome? a trinetx-based analysis (2025)

Blood DOI OpenAlex
AKI in Patients Receiving Chimeric Antigen Receptor T Cells: Risk Factors and Characteristics (2025)

Journal of the American Society of Nephrology DOI OpenAlex
Revaccination status after bone marrow transplant and chimeric antigen receptor T-cell therapy. (2025)

JCO Oncology Practice DOI OpenAlex
Efficacy and safety of two-year fixed versus continuous immune checkpoint inhibitor therapy in advanced or metastatic non-small cell lung cancer: a systematic review (2025)

Cancer Immunology Immunotherapy 2 citations DOI OpenAlex
MRI lesion burden as a predictor of progression and survival in smoldering multiple myeloma. (2025)

Journal of Clinical Oncology DOI OpenAlex
Survival and safety of two year-fixed duration vs continuous immune checkpoint inhibitor therapy in advanced or metastatic NSCLC: A systematic review. (2025)

Journal of Clinical Oncology DOI OpenAlex
Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience (2025)

Bone Marrow Transplantation DOI OpenAlex
A Case Report on Pulmonary Tumor Embolism in a Patient With a Metastatic Gastrointestinal Stromal Tumor Invading the Inferior Vena Cava: Tumor or Thrombus? (2025)

Cureus DOI OpenAlex
Simultaneous Presentation of Relapsed Diffuse Large B-cell Lymphoma and Extrapulmonary Tuberculosis in a Patient With HIV: A Case Report (2025)

Cureus DOI OpenAlex
Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience (2024)

Blood DOI OpenAlex